Expert Opinion on Pharmacotherapy最新文献_第2页

Selecting optimal therapy in systemic mastocytosis: current state and future directions. 选择全身性肥大细胞增多症的最佳治疗方法：现状和未来方向。

IF 2.5 3区医学

Expert Opinion on Pharmacotherapy Pub Date : 2025-05-12 DOI: 10.1080/14656566.2025.2503847

Ifeoma Ike, Victor Samperio, Constantin A Dasanu

引用次数: 0

Conditional marketing authorisation of therapeutic medicines for solid tumours in the European Union: methodological and clinical challenges. 欧盟实体肿瘤治疗药物的有条件上市许可：方法学和临床挑战

IF 2.5 3区医学

Expert Opinion on Pharmacotherapy Pub Date : 2025-05-11 DOI: 10.1080/14656566.2025.2504699

Stefania Bellino, Anna La Salvia

引用次数: 0

Beyond the injection: delivery systems reshaping retinal disease management. 注射之外：传递系统重塑视网膜疾病管理。

IF 2.5 3区医学

Expert Opinion on Pharmacotherapy Pub Date : 2025-05-11 DOI: 10.1080/14656566.2025.2496424

Lucas W Rowe, Christian Akotoye, Alon Harris, Thomas A Ciulla

{"title":"Beyond the injection: delivery systems reshaping retinal disease management.","authors":"Lucas W Rowe, Christian Akotoye, Alon Harris, Thomas A Ciulla","doi":"10.1080/14656566.2025.2496424","DOIUrl":"https://doi.org/10.1080/14656566.2025.2496424","url":null,"abstract":"Introduction: Intravitreal injections remain the standard for treating common retinal diseases including age-related macular degeneration (AMD), diabetic macular edema (DME) and diabetic retinopathy. However, frequent administration creates significant treatment burden due to limited drug half-life and the chronic nature of these conditions.Areas covered: This review summarizes emerging drug delivery techniques and therapies for retinal disease that have achieved FDA approval within the past five years or have advanced to Phase 3 development, including intravitreal sustained-release platforms and alternative delivery routes (suprachoroidal, subretinal, topical, and subcutaneous). Specific innovations discussed include the ranibizumab port delivery system, EYP-1901 (Duravyu, vorolanib implant), KSI-301 (tarcocimab tedromer), KSI-501, OTX-TKI (Axpaxli, axitinib implant), 4D-150, revakinagene taroretcel-lwey (Encelto, NT-501, encapsulated cell therapy), Xipere (triamcinolone acetonide injectable suspension), AU-011 (belzupacap sarotalocan targeted delivery), ABBV-RGX-314, elamipretide, and OCS-01 (high concentration dexamethasone).Expert opinion: Promising innovations include sustained-release intravitreal implants, topical and subcutaneous delivery systems, and targeted methods like suprachoroidal and subretinal injections, each with unique advantages and limitations. Challenges include overcoming the blood-retinal barrier, surgical complications with implantable devices, and ensuring patient adherence. Advances in smart delivery systems, drug formulations, and predictive models, alongside interdisciplinary collaboration, will be crucial in achieving personalized, effective, and sustainable retinal therapies.","PeriodicalId":12184,"journal":{"name":"Expert Opinion on Pharmacotherapy","volume":" ","pages":"1-14"},"PeriodicalIF":2.5,"publicationDate":"2025-05-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143989580","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The effectiveness of the current lipid-lowering therapy for refractory dyslipidaemia in patients with coronary artery disease: the price of 'the lower, the better' - results of a survey by Japanese cardiologists. 当前降脂治疗冠心病难治性血脂异常的有效性：价格“越低越好”——日本心脏病专家的一项调查结果。

IF 2.5 3区医学

Expert Opinion on Pharmacotherapy Pub Date : 2025-05-11 DOI: 10.1080/14656566.2025.2503853

Satoru Hashimoto, Yoshihiro Motozawa, Toshiki Mano

{"title":"The effectiveness of the current lipid-lowering therapy for refractory dyslipidaemia in patients with coronary artery disease: the price of 'the lower, the better' - results of a survey by Japanese cardiologists.","authors":"Satoru Hashimoto, Yoshihiro Motozawa, Toshiki Mano","doi":"10.1080/14656566.2025.2503853","DOIUrl":"https://doi.org/10.1080/14656566.2025.2503853","url":null,"abstract":"Background: Optimal medical therapy plays a critical role in improving the prognosis of patients with coronary artery disease (CAD), particularly through the management of dyslipidaemia. This study investigated treatment practices for patients with dyslipidaemia-complicated CAD (DL-CAD) in Japan, focusing on cases considered refractory to standard management.Research design and methods: A web-based survey was conducted from 10 November 2023 to 1 December 2023 among cardiologists. Responses from 202 participants were analysed and divided into two groups based on the proportion of patients with refractory DL-CAD: <10% (n = 102) and ≥ 10% (n = 100).Results: There was no significant difference in the use of maximally tolerated statins between groups. However, ezetimibe, EPA, and omega-3-acid ethyl esters were used more frequently in the group with a higher proportion of refractory patients. Logistic regression analysis revealed that the use of ezetimibe was the only factor affecting the proportion of patients with refractory DL-CAD (odds ratio: 1.26, p = 0.0499).Conclusions: Japanese cardiologists tend to prescribe ezetimibe in addition to maximally tolerated statin for patients with refractory DL-CAD. Furthermore, they are increasingly targeting elevated triglycerides using polyunsaturated fatty acids as a strategy to reduce residual cardiovascular risk when LDL-C targets are unmet.","PeriodicalId":12184,"journal":{"name":"Expert Opinion on Pharmacotherapy","volume":" ","pages":"1-8"},"PeriodicalIF":2.5,"publicationDate":"2025-05-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143975561","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Pharmacotherapy of treatment-resistant hypertension in patients with chronic kidney disease. 慢性肾病患者难治性高血压的药物治疗

IF 2.5 3区医学

Expert Opinion on Pharmacotherapy Pub Date : 2025-05-08 DOI: 10.1080/14656566.2025.2503854

Panagiotis I Georgianos, Christodoula Kourtidou, Ariti Tsinari, Vasilios Vaios, Konstantinos Leivaditis, Vassilios Liakopoulos

引用次数: 0

Selecting optimal therapy for advanced non-functional pancreatic neuroendocrine tumors: latest research and therapeutic advances. 晚期非功能性胰腺神经内分泌肿瘤的最佳治疗选择：最新研究和治疗进展。

IF 2.5 3区医学

Expert Opinion on Pharmacotherapy Pub Date : 2025-05-07 DOI: 10.1080/14656566.2025.2501142

Ruba Alchaikh Hassan, Arti Patel, Constantin A Dasanu

引用次数: 0

Advances in pharmacotherapy of juvenile idiopathic arthritis. 青少年特发性关节炎的药物治疗进展。

IF 2.5 3区医学

Expert Opinion on Pharmacotherapy Pub Date : 2025-05-03 DOI: 10.1080/14656566.2025.2501146

Stephanie K A Wong, Simone Appenzeller, Marinka Twilt

引用次数: 0

Improving the treatment of Pompe disease with enzyme replacement therapy: current strategies and clinical evidence. 用酶替代疗法改善Pompe病的治疗：当前策略和临床证据

IF 2.5 3区医学

Expert Opinion on Pharmacotherapy Pub Date : 2025-05-01 Epub Date: 2025-04-16 DOI: 10.1080/14656566.2025.2491508

Alberto Corsini

{"title":"Improving the treatment of Pompe disease with enzyme replacement therapy: current strategies and clinical evidence.","authors":"Alberto Corsini","doi":"10.1080/14656566.2025.2491508","DOIUrl":"https://doi.org/10.1080/14656566.2025.2491508","url":null,"abstract":"Introduction: Pompe disease (PD) is a rare genetic disorder that leads to intralysosomal glycogen accumulation because of a deficiency in the lysosomal enzyme acid α-glucosidase (GAA), which is required to break down glycogen to glucose. Enzyme replacement therapy (ERT) with recombinant human GAA (rhGAA) supplies exogenous GAA to reduce glycogen deposits, thereby improving motor and respiratory functioning.Area covered: The first approved ERT for PD was the rhGAA alglucosidase alfa. Limitations associated with this treatment led to the development of two other rhGAAs: avalglucosidase alfa and cipaglucosidase alfa. This review describes the limitations of alglucosidase alfa and focuses on the strategies used to overcome these limitations, including the conjugation of multiple synthetic bis-M6P - containing hexasaccharides to sialic acids present on the enzyme, thus enhancing M6PR targeting, enzyme uptake, glycogen clearance, and therapeutic outcomes. Efficacy and safety of avalglucosidase alfa in late-onset and infantile-onset PD are also discussed. A brief overview of the newest ERT, cipaglucosidase alfa, is also provided.Expert opinion: While ERT for PD continues to improve with more effective enzymes like avalglucosidase alfa, the future lies in integrated approaches that combine different therapeutic modalities (gene therapy, substrate reduction therapy) and the use of biomarkers to individualize treatment.","PeriodicalId":12184,"journal":{"name":"Expert Opinion on Pharmacotherapy","volume":"26 7","pages":"835-848"},"PeriodicalIF":2.5,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143971591","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Developments in pharmacotherapy for the preservation of ovarian function during cancer treatment. 在癌症治疗期间保存卵巢功能的药物治疗进展。

IF 2.5 3区医学

Expert Opinion on Pharmacotherapy Pub Date : 2025-05-01 Epub Date: 2025-04-25 DOI: 10.1080/14656566.2025.2495090

Volkan Turan, Kutluk Oktay

{"title":"Developments in pharmacotherapy for the preservation of ovarian function during cancer treatment.","authors":"Volkan Turan, Kutluk Oktay","doi":"10.1080/14656566.2025.2495090","DOIUrl":"https://doi.org/10.1080/14656566.2025.2495090","url":null,"abstract":"Introduction: Cancer is one of the major causes of human death, and anti-cancer therapy often results in premature ovarian failure and infertility, depending on factors such as age, initial ovarian reserve, and chemotherapy type and dose. Fertility preservation procedures, such as oocyte, embryo, and ovarian cortex cryopreservation, can help women achieve pregnancy after cancer treatment. However, the development of pharmacological therapies to protect ovarian function during chemotherapy would represent a significant advancement.Areas covered: We searched the published articles in PubMed up to December 2024, containing key words '\"chemotherapy\",' 'cancer,' '\"ovarian protection\",' '\"pharmacological therapy\",' '\"ovarian reserve\"' and '\"fertility\".' Chemotherapeutic agents act via various mechanisms in the human ovary, including direct DNA damage leading to oocyte apoptosis, as well as damage to ovarian stroma and microvascular architecture. In recent years, numerous protective agents have emerged, showing promise in protecting ovaries from chemotherapy-induced damage. However, most studies have relied on animal models, and only a limited number have directly tested these agents in human ovarian tissue. At present, no pharmacological treatment has been conclusively proven effective for preserving fertility.Expert opinion: A comprehensive understanding of the mechanisms underlying chemotherapy-induced ovarian damage is critical for the development of efficient and targeted pharmacological therapies.","PeriodicalId":12184,"journal":{"name":"Expert Opinion on Pharmacotherapy","volume":"26 7","pages":"897-907"},"PeriodicalIF":2.5,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144005215","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Past, present and future of respiratory syncytial infection prevention in infants and young children. 婴幼儿呼吸道合胞体感染预防的过去、现在和未来。

IF 2.5 3区医学

Expert Opinion on Pharmacotherapy Pub Date : 2025-05-01 Epub Date: 2025-04-22 DOI: 10.1080/14656566.2025.2495091

Susanna Esposito, Nicola Principi

引用次数: 0